(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 271.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Crinetics Pharmaceuticals's revenue in 2026 is $7,696,000.On average, 16 Wall Street analysts forecast CRNX's revenue for 2026 to be $6,608,476,903, with the lowest CRNX revenue forecast at $3,796,615,266, and the highest CRNX revenue forecast at $8,619,342,766. On average, 15 Wall Street analysts forecast CRNX's revenue for 2027 to be $18,812,406,641, with the lowest CRNX revenue forecast at $13,709,068,857, and the highest CRNX revenue forecast at $23,516,817,118.
In 2028, CRNX is forecast to generate $44,663,105,565 in revenue, with the lowest revenue forecast at $33,451,258,828 and the highest revenue forecast at $68,932,754,006.